Amedisys Historical Income Statement

AMED Stock

USD 90.16 0.16 0.18%

Historical analysis of Amedisys income statement accounts such as Interest Expense of 32.8 M, Selling General Administrative of 333.3 M or Total Revenue of 2.3 B can show how well Amedisys performed in making a profits. Evaluating Amedisys income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Amedisys's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Amedisys latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amedisys is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

About Amedisys Income Statement Analysis

Amedisys Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Amedisys shareholders. The income statement also shows Amedisys investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Amedisys Income Statement Chart

At present, Amedisys' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Gross Profit is forecasted to decline to about 447.4 M.

Selling General Administrative Total Revenue Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Amedisys generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Amedisys. It is also known as Amedisys overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Amedisys' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Gross Profit is forecasted to decline to about 447.4 M.

	2021	2022	2023	2024 (projected)
Gross Profit	980.8M	962.8M	457.1M	447.4M
Total Revenue	2.2B	2.2B	2.2B	2.3B

Gross Profit Total Revenue

Amedisys income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Total Other Income Expense Net	Net Income	Income Tax Expense	Income Before Tax	Extraordinary Items	Minority Interest	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.11	0.48	0.37	0.54	0.44	-0.18	-0.12	-0.04	0.21	0.46	-0.16	-0.12	-0.24	-0.16	-0.54	-0.24	-0.25	0.26	0.01	0.11	0.01	-0.18	-0.04	0.23	0.18
Interest Expense	0.11		0.05	0.73	0.13	0.71	0.35	0.35	0.36	0.88	0.58	-0.41	0.07	0.39	0.15	-0.24	0.06	0.0	-0.13	-0.24	0.4	0.44	0.69	-0.94	0.64	-0.81
Selling General Administrative	0.48	0.05		0.63	0.94	0.55	0.37	0.41	0.45	0.33	0.32	0.17	0.5	0.29	0.46	-0.73	-0.08	0.32	-0.19	0.37	0.63	0.4	-0.58	-0.05	0.45	0.33
Total Revenue	0.37	0.73	0.63		0.72	0.96	0.48	0.47	0.51	0.93	0.74	-0.1	0.34	0.49	0.39	-0.69	0.14	0.16	-0.14	0.12	0.65	0.72	0.15	-0.7	0.75	-0.44
Gross Profit	0.54	0.13	0.94	0.72		0.7	0.27	0.26	0.3	0.42	0.55	0.26	0.36	0.22	0.34	-0.75	0.01	0.18	0.05	0.35	0.5	0.48	-0.52	-0.13	0.53	0.28
Other Operating Expenses	0.44	0.71	0.55	0.96	0.7		0.23	0.21	0.25	0.89	0.9	-0.11	0.08	0.26	0.13	-0.72	0.12	-0.1	0.13	0.03	0.47	0.59	0.19	-0.63	0.65	-0.42
Operating Income	-0.18	0.35	0.37	0.48	0.27	0.23		0.95	0.94	0.49	-0.19	0.21	0.94	0.95	0.97	-0.04	0.33	0.91	-0.84	0.3	0.73	0.73	-0.09	-0.5	0.64	-0.23
Ebit	-0.12	0.35	0.41	0.47	0.26	0.21	0.95		1.0	0.49	-0.23	-0.04	0.91	0.89	0.93	-0.11	0.13	0.86	-0.89	0.35	0.78	0.65	-0.03	-0.45	0.58	-0.24
Ebitda	-0.04	0.36	0.45	0.51	0.3	0.25	0.94	1.0		0.51	-0.19	-0.05	0.9	0.88	0.92	-0.15	0.11	0.84	-0.87	0.35	0.8	0.66	-0.04	-0.46	0.6	-0.23
Cost Of Revenue	0.21	0.88	0.33	0.93	0.42	0.89	0.49	0.49	0.51		0.68	-0.27	0.25	0.52	0.33	-0.51	0.18	0.12	-0.2	-0.02	0.59	0.69	0.46	-0.84	0.71	-0.71
Total Operating Expenses	0.46	0.58	0.32	0.74	0.55	0.9	-0.19	-0.23	-0.19	0.68		-0.12	-0.34	-0.14	-0.29	-0.63	0.06	-0.48	0.53	-0.09	0.1	0.3	0.27	-0.46	0.42	-0.36
Total Other Income Expense Net	-0.16	-0.41	0.17	-0.1	0.26	-0.11	0.21	-0.04	-0.05	-0.27	-0.12		0.34	0.23	0.33	0.12	0.55	0.38	0.03	0.31	-0.05	0.24	-0.63	0.26	0.07	0.44
Net Income	-0.12	0.07	0.5	0.34	0.36	0.08	0.94	0.91	0.9	0.25	-0.34	0.34		0.85	0.99	-0.04	0.27	0.97	-0.83	0.42	0.68	0.61	-0.37	-0.23	0.54	0.07
Income Tax Expense	-0.24	0.39	0.29	0.49	0.22	0.26	0.95	0.89	0.88	0.52	-0.14	0.23	0.85		0.91	-0.05	0.31	0.82	-0.76	0.33	0.73	0.81	-0.03	-0.51	0.57	-0.31
Income Before Tax	-0.16	0.15	0.46	0.39	0.34	0.13	0.97	0.93	0.92	0.33	-0.29	0.33	0.99	0.91		-0.04	0.31	0.96	-0.84	0.41	0.71	0.68	-0.3	-0.31	0.57	-0.02
Extraordinary Items	-0.54	-0.24	-0.73	-0.69	-0.75	-0.72	-0.04	-0.11	-0.15	-0.51	-0.63	0.12	-0.04	-0.05	-0.04		0.06	0.2	-0.09	-0.18	-0.62	-0.25	0.16	0.08	-0.16	-0.03
Minority Interest	-0.24	0.06	-0.08	0.14	0.01	0.12	0.33	0.13	0.11	0.18	0.06	0.55	0.27	0.31	0.31	0.06		0.3	-0.21	0.12	0.07	0.37	-0.01	-0.23	0.28	-0.16
Net Income From Continuing Ops	-0.25	0.0	0.32	0.16	0.18	-0.1	0.91	0.86	0.84	0.12	-0.48	0.38	0.97	0.82	0.96	0.2	0.3		-0.83	0.37	0.51	0.54	-0.33	-0.21	0.49	0.07
Non Recurring	0.26	-0.13	-0.19	-0.14	0.05	0.13	-0.84	-0.89	-0.87	-0.2	0.53	0.03	-0.83	-0.76	-0.84	-0.09	-0.21	-0.83		-0.19	-0.64	-0.41	0.05	0.28	-0.31	0.15
Non Operating Income Net Other	0.01	-0.24	0.37	0.12	0.35	0.03	0.3	0.35	0.35	-0.02	-0.09	0.31	0.42	0.33	0.41	-0.18	0.12	0.37	-0.19		0.28	0.37	-0.37	0.25	0.14	0.25
Discontinued Operations	0.11	0.4	0.63	0.65	0.5	0.47	0.73	0.78	0.8	0.59	0.1	-0.05	0.68	0.73	0.71	-0.62	0.07	0.51	-0.64	0.28		0.55	-0.08	-0.35	0.39	-0.18
Tax Provision	0.01	0.44	0.4	0.72	0.48	0.59	0.73	0.65	0.66	0.69	0.3	0.24	0.61	0.81	0.68	-0.25	0.37	0.54	-0.41	0.37	0.55		-0.06	-0.57	0.68	-0.3
Interest Income	-0.18	0.69	-0.58	0.15	-0.52	0.19	-0.09	-0.03	-0.04	0.46	0.27	-0.63	-0.37	-0.03	-0.3	0.16	-0.01	-0.33	0.05	-0.37	-0.08	-0.06		-0.57	0.1	-0.86
Net Interest Income	-0.04	-0.94	-0.05	-0.7	-0.13	-0.63	-0.5	-0.45	-0.46	-0.84	-0.46	0.26	-0.23	-0.51	-0.31	0.08	-0.23	-0.21	0.28	0.25	-0.35	-0.57	-0.57		-0.76	0.74
Reconciled Depreciation	0.23	0.64	0.45	0.75	0.53	0.65	0.64	0.58	0.6	0.71	0.42	0.07	0.54	0.57	0.57	-0.16	0.28	0.49	-0.31	0.14	0.39	0.68	0.1	-0.76		-0.34
Selling And Marketing Expenses	0.18	-0.81	0.33	-0.44	0.28	-0.42	-0.23	-0.24	-0.23	-0.71	-0.36	0.44	0.07	-0.31	-0.02	-0.03	-0.16	0.07	0.15	0.25	-0.18	-0.3	-0.86	0.74	-0.34

Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	63.3M	28.8M	30.9M	24.9M	23.8M	18.6M
Interest Expense	14.5M	11.0M	9.5M	22.2M	31.3M	32.8M
Selling General Administrative	607.9M	668.3M	711.2M	754.1M	264.0M	333.3M
Total Revenue	2.0B	2.1B	2.2B	2.2B	2.2B	2.3B
Gross Profit	805.3M	886.2M	980.8M	962.8M	457.1M	447.4M
Other Operating Expenses	1.8B	1.8B	2.0B	2.0B	2.1B	2.2B
Operating Income	177.5M	219.3M	251.9M	180.8M	156.4M	164.2M
Ebit	177.5M	221.9M	289.8M	182.5M	193.1M	202.7M
Ebitda	240.7M	250.7M	320.7M	207.4M	216.9M	227.8M
Cost Of Revenue	1.2B	1.2B	1.2B	1.3B	1.8B	1.9B
Total Operating Expenses	626.4M	662.7M	728.8M	779.0M	834.5M	876.2M
Total Other Income Expense Net	(7.1M)	(8.4M)	28.3M	(20.5M)	(116.8M)	(110.9M)
Net Income	126.8M	183.6M	209.1M	118.6M	(9.7M)	(9.3M)
Income Tax Expense	42.5M	25.6M	70.1M	42.5M	50.6M	53.1M
Income Before Tax	170.4M	210.8M	280.2M	160.2M	39.6M	45.7M
Net Income Applicable To Common Shares	126.8M	183.6M	209.1M	118.6M	136.4M	143.2M
Minority Interest	1.1M	1.6M	1.1M	(910K)	1.1M	1.1M
Net Income From Continuing Ops	127.9M	185.2M	210.2M	117.7M	1.6M	1.5M
Non Operating Income Net Other	7.5M	2.6M	37.8M	1.7M	2.0M	1.9M
Tax Provision	42.5M	25.6M	70.1M	42.5M	50.2M	42.3M
Interest Income	78K	292K	49K	178K	2.5M	2.6M
Net Interest Income	(14.4M)	(10.7M)	(9.5M)	(22.1M)	(26.3M)	(25.0M)
Reconciled Depreciation	54.3M	67.9M	71.3M	71.0M	59.9M	55.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.35)

Earnings Share

2.52

Revenue Per Share

71.004

Quarterly Revenue Growth

0.057

Return On Assets

0.0627

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Historical Income Statement

About Amedisys Income Statement Analysis

Amedisys Income Statement Chart

Total Revenue

Other Operating Expenses

Amedisys income statement Correlations

Amedisys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amedisys income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 0.99	Net Income
Income Before Tax	+ 0.97	Operating Income
Net Income From Continuing Ops	+ 0.97	Net Income
Other Operating Expenses	+ 0.96	Total Revenue
Net Income From Continuing Ops	+ 0.96	Income Before Tax

Net Interest Income	- 0.94	Interest Expense
Non Recurring	- 0.89	Ebit
Non Recurring	- 0.87	Ebitda
Selling And Marketing Expenses	- 0.86	Interest Income
Non Recurring	- 0.84	Income Before Tax
Net Interest Income	- 0.84	Cost Of Revenue